Michael Obuchowski News
-
Apple Inc. shares rose to a record after quarterly profit more than doubled as holiday demand for the iPhone and iPad cemented its position as the most valuable technology company.
-
For acquirers willing to wager on the future of solar power, First Solar Inc. has gotten $22 billion cheaper.
-
Apple Inc. fell in U.S. trading after profit missed analysts’ predictions for the first time in at least six years, evidence that customers delayed iPhone purchases before the release of the latest model.
-
Takeda Pharmaceutical Co. is pursuing its biggest acquisition after destroying more value for shareholders than any drugmaker and hoarding the most cash.
-
The rally in solar shares after Japan ’s atomic accident may fizzle because the crisis won’t quickly boost demand for renewable power, investors including First Empire Asset Management’s Michael Obuchowski said.
-
Henri Termeer , a biotech industry pioneer and chief executive officer at Genzyme Corp ., is on the verge of losing control of the company he transformed from a start-up in 1983 into a cutting-edge drugmaker with $4.5 billion in annual sales.
-
Genzyme Corp. started talks with Takeda Pharmaceutical Co. to try to sell itself for more than $18.5 billion, the Mail on Sunday reported , citing a person familiar with the matter.
-
Apple Inc. reported net income and sales that soared past analysts’ estimates as Chief Executive Officer Steve Jobs promised to release “more extraordinary products” this year. The shares rose in late trading.
-
Options contracts on Genzyme Corp.’s multiple sclerosis drug would decrease Sanofi-Aventis SA’s cost by as much as $1.6 billion in a takeover of the world’s largest maker of treatments for rare genetic diseases.
-
Apple Inc. fell the most in two months on the Nasdaq after forecasting shrinking gross margins and profit that missed some analysts’ estimates, indicating that the company is making less from each iPhone and iPad it sells.
|
|
Most Popular on Bloomberg
|
|
Michael Obuchowski Videos
|
|